MENU
BBH
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

BBH stock forecast, quote, news & analysis

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® U... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
BBH
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for BBH with price predictions
Oct 30, 2026

Momentum Indicator for BBH turns positive, indicating new upward trend

BBH saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 97 similar instances where the indicator turned positive. In 84 of the 97 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for BBH just turned positive on October 20, 2026. Looking at past instances where BBH's MACD turned positive, the stock continued to rise in 39 of 51 cases over the following month. The odds of a continued upward trend are 76%.

Following a +1.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where BBH advanced for three days, in 249 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

The Aroon Indicator entered an Uptrend today. In 205 of 255 cases where BBH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

BBH broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), IQVIA Holdings (NYSE:IQV), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Guardant Health (NASDAQ:GH).

Industry description

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® U.S. Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Market Cap

The average market capitalization across the VanEck Biotech ETF (BBH) ETF is 48.12B. The market cap for tickers in the group ranges from 10.37B to 251.64B. AMGN holds the highest valuation in this group at 251.64B. The lowest valued company is QGEN at 10.37B.

High and low price notable news

The average weekly price growth across all stocks in the VanEck Biotech ETF (BBH) ETF was 19%. For the same ETF, the average monthly price growth was 31%, and the average quarterly price growth was 353%. INSM experienced the highest price growth at 21%, while ALNY experienced the biggest fall at -26%.

Volume

The average weekly volume growth across all stocks in the VanEck Biotech ETF (BBH) ETF was 22%. For the same stocks of the ETF, the average monthly volume growth was 27% and the average quarterly volume growth was 2%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 56
Price Growth Rating: 38
SMR Rating: 67
Profit Risk Rating: 69
Seasonality Score: 23 (-100 ... +100)